Source comparison
Is MK-677 Better Than Ibutamoren?: Comparison
This table clarifies the naming confusion and compares the compound to related growth hormone modulators. MK-677 Ibutamoren mesylate Ghrelin receptor agonist (GHS-R1a). Stimulates endogenous GH release Oral: 60–65% (non-peptide structure) IGF-1 elevation studi
This comparison does not assign a generated winner or score.
- This table clarifies the naming confusion and compares the compound to related growth hormone modulators.
- MK-677
- Ibutamoren mesylate
- Ghrelin receptor agonist (GHS-R1a). Stimulates endogenous GH release
- Oral: 60–65% (non-peptide structure)
- IGF-1 elevation studies, body composition research, bone density protocols
- Same compound as ibutamoren. Name preference doesn't affect mechanism or outcomes
- Ibutamoren
- Identical to MK-677. GHS-R1a activation
- Oral: 60–65%
- Muscle wasting research, aging studies, metabolic function
- INN (international nonproprietary name). More formal designation for same molecule
- GHRP-2
- Growth Hormone Releasing Peptide-2
- GHS-R1a agonist (peptide-based)
- Injectable only: proteolytic degradation orally
- GH pulse studies, short-term GH elevation protocols
- Requires injection; shorter half-life (30 min). More frequent dosing needed
- Hexarelin
- Examorelin
- GHS-R1a agonist with desensitization liability
- Injectable: peptide structure
- Cardioprotective research, acute GH stimulation
- Potent but chronic use causes receptor desensitization within 4–6 weeks
- rhGH (Somatropin)
- Recombinant human growth hormone
- Direct GH replacement. Suppresses endogenous production
- Injectable: protein structure
- Clinical GH deficiency, severe wasting syndromes
- Gold standard for pathological deficiency; inappropriate for research into natural GH optimization